Array BioPharma (ARRY) PT Raised to $35 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Array Biopharma (ARRY) PT Set at Street High of $37 at Wells Fargo, Guggenheim - Bloomberg
May 21, 2019 2:23 PM EDTArray Biopharma (NASDAQ: ARRY) PT Set at Street High of $37 at Wells Fargo, Guggenheim - Bloomberg
Buy Array BioPharma (ARRY) On Weakness Surrounding Triplet Data - Stifel
May 21, 2019 9:32 AM EDTStifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on Array BioPharma (NASDAQ: ARRY) after the company announced long-awaited interim top-line results from the P3 BEACON trial evaluating the combination of BRAFTOVI/MEKTOVI/cetuximab (triplet) vs. combinations of both BRAFTOVI/cetuximab (doublet) and... More
Array Biopharma (ARRY) Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial
May 21, 2019 8:01 AM EDTArray BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor, and ERBITUX® (cetuximab), an anti-EGFR antibody (BRAFTOVI Triplet), in patients with... More
